Clinical Phase 2 Study of Trastuzumab emtansine (Genetical Recombination) (T-DM1) in Patients with inoperable or Recurrent HER2-positive Breast Cancer
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 08 Jun 2016 New trial record